Search Results | Blood | American Society of Hematology

1-20 of 216

2 3 4 5

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood blood.2020008825.

DOI: https://doi.org/10.1182/blood.2020008825

Published: 2020

Includes: Supplemental data

Journal Articles

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Felix Korell, MD, Thomas Luft, MD, PhD, Michael Schmitt, MD, Sascha Dietrich, MD, Anita Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger, MD

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-139615

Published: 2020

Journal Articles

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Viktoria Blumenberg, MD, Maria-Luisa Schubert, MD, Eli Zamir, Sabine Schmidt, Roman Rohrbach, Philipp Waldhoff, Daria Bozic, Hendrik Pock, MD, Eran Elinav, Christian Schmidt, MD, Veit Buecklein, MD, Carsten Müller-Tidow, MD, Peter Dreger, MD, Michael von Bergwelt, MD PhD, Michael Schmitt, MD, Marion Subklewe, MD, Christoph Stein-Thöringer, MD

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-141210

Published: 2020

Journal Articles

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-137528

Published: 2020

Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Blood (2020) 136 (Supplement 1): 11–13.

DOI: https://doi.org/10.1182/blood-2020-136539

Published: 2020

Journal Articles

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 698.

DOI: https://doi.org/10.1182/blood-2019-125802

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

DOI: https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 4574.

DOI: https://doi.org/10.1182/blood-2019-127238

Published: 2019

Journal Articles

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Ruben A. Gößmann, Lei Wang, MD, Ming Ni, Mingya Yang, MD, Thomas Luft, Ute Hegenbart, MD, Stefan O. Schönland, MD, Patrick Wuchter, MD, Volker Eckstein, William Hermann Krüger, MD PhD, Ronit Yerushalmi, MD, Katia Beider, Arnon Nagler, MD MSc, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 3287.

DOI: https://doi.org/10.1182/blood-2019-125049

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Lindsey E. Roeker, MD, Jennifer R. Brown, MD PhD, Peter Dreger, Oscar B Lahoud, MD, Toby A. Eyre, MBBChir, MRCP, Danielle M. Brander, MD, Alan Skarbnik, MD, Catherine C. Coombs, MD, Haesook T. Kim, PhD, Steven T Manchini, BS, Timothy J Voorhees, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Harriet S Walter, Arvind K. Arumainathan, FRCPath, MBBS, MRCP,, Andrea Sitlinger, MD, Craig S. Sauter, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 3321.

DOI: https://doi.org/10.1182/blood-2019-124140

Published: 2019

Journal Articles

Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry

Dietrich W. Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stoelzel, MD, Fabio Ciceri, MD, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz

Blood (2019) 134 (Supplement_1): 3326.

DOI: https://doi.org/10.1182/blood-2019-127108

Published: 2019

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, MD, Thomas Luft, MD PhD, Andrea Bondong, Ute Hegenbart, MD, Julia Meissner, MD, Nora Liebers, Michael Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger

Blood (2019) 134 (Supplement_1): 3328.

DOI: https://doi.org/10.1182/blood-2019-128352

Published: 2019

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Eugen Tausch, Volkmar Boehme, Matthias Ritgen, Ruediger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Stephan Stilgenbauer, Danjie Zhang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 4297.

DOI: https://doi.org/10.1182/blood-2019-130912

Published: 2019

Journal Articles

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Thomas Luft, MD PhD, Hao Dai, Aleksandar Radujkovic, MD, David Schult, Joshua Majer-Lauterbach, Olga Blau, MD PhD, Lars Bullinger, Sihe Jiang, Carsten Müller-Tidow, MD, Peter Dreger, Olaf Penack, MD

Blood (2019) 134 (Supplement_1): 4487.

DOI: https://doi.org/10.1182/blood-2019-124284

Published: 2019

Journal Articles

High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation

Lambros Kordelas, MD, Aleksandar Radujkovic, MD, Hao Dai, Rashit Bogdanov, PhD, Dietrich W. Beelen, Carsten Müller-Tidow, MD, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 4507.

DOI: https://doi.org/10.1182/blood-2019-124278

Published: 2019

Journal Articles

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Mingya Yang, MD, Lei Wang, MD, Ming Ni, Maria-Luisa Schubert, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Ruben A. Gößmann, Christian Kleist, Volker Eckstein, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 5620.

DOI: https://doi.org/10.1182/blood-2019-125622

Published: 2019

Journal Articles

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

Patrick Derigs, MD, Maria-Luisa Schubert, MD, Paul Schnitzler, PhD, Carsten Müller-Tidow, MD, Thomas Luft, MD PhD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 5650.

DOI: https://doi.org/10.1182/blood-2019-125675

Published: 2019

Journal Articles

The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients

Hao Dai, Sivaramakrishna P. Rachakonda, PhD, Olaf Penack, MD, Aleksandar Radujkovic, MD, Carsten Müller-Tidow, MD, Rajiv Kumar, PhD, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 873.

DOI: https://doi.org/10.1182/blood-2019-124742

Published: 2019

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

DOI: https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Easix for Prediction of Survival in Myelodysplastic Syndromes

Almuth Maria Anni Merz, MD, Ulrich Germing, MD, Guido Kobbe, MD, Jennifer Kaivers, MD, Anna Jauch, Aleksandar Radujkovic, MD, Manuela Hummel, Axel Benner, Maximilian Merz, Peter Dreger, Thomas Luft, MD PhD

Blood (2019) 134 (Supplement_1): 1722.

DOI: https://doi.org/10.1182/blood-2019-122622

Published: 2019

2 3 4 5

NARROW

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation

The Effect of Apoptosis Inhibitor Blockade Agents on the Third Generation CD19 CAR T Cells

Letermovir Prophylaxis Is Effective for Cytomegalovirus Reactivation after Allogeneic Hematopoietic Cell Transplantation: Single Center Real-World Data

The CXCL9 Polymorphism rs884304 Associates with Early CXCL9 Reconstitution and with Severe Chronic Graft-Versus-Host Disease (cGVHD) in Human Allograft Recipients

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Easix for Prediction of Survival in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only